MedWatch

Everything you need to know about orphan drugs

Do you know how great the success rate for orphan drugs is compared with traditional medicine? How big the global market for niche medicine is? Or how great the unused potential within development of medicine for rare diseases really is?

Foto: Jyllands-Posten

The pharmaceutical and biotech industry has been rapidly entering the market for so-called orphan drugs – medicine targeting rare diseases.

After the FDA in 1983 decided to ease restrictions for the development of this type of drug, and European health authorities followed suit in 2000, giving the industry greater incentives to develop medicine for rare diseases, it has become far more attractive to focus on orphan drugs.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier